NCT05085483已完成不适用
Efficacy of an Orally Administrated Nutritional Ketogenic Supplement, for the Prevention of Episodic Migraine: a Randomized, Double-blind, Placebo-controlled, Cross-over Trial
Société des Produits Nestlé (SPN)2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2021年10月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 2
- 主要终点
- Mean change from baseline in MDM versus placebo
研究概览
简要总结
Efficacy of a nutritional ketogenic supplement (NKS) in reducing the number, intensity, and duration of migraine headaches in episodic migraine patients.
详细描述
The KEMIP study is a randomized, placebo-controlled, double-blind, full cross-over, study to test the efficacy of NKS at reducing migraine days per month (MDM) compared to placebo in episodic migraine participants.
Participants will prompted to enter data on migraine headache features (duration, pain intensity, medication use, symptoms) and product intake in an eDiary every day throughout the course of the study.
Each participant will complete five steps of 1 month each: (1) baseline evaluation; (2) NKS/placebo intake; (3) washout & cross-over; (4) NKS/placebo intake; (5) follow-up
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged ≥18 years who have previously been diagnosed with migraine, with or without aura, in accordance with the ICHD-3 Classification criteria;
- •Have an estimated frequency of 5 to 14 MDM in each of the 3 months prior to enrolment;
- •In principle, agree at the beginning (virtual call V0) to adequately complete a headache electronic diary (e-Diary) on at least 24 days out of the 28 days in the run-in baseline period;
- •In practice, adequately complete by the end of V1 a headache eDiary on at least 24 days out of the 28 days in the run-in baseline period;
- •Agree to refrain from initiating or changing the type, dosage, or frequency of any prophylactic medications against migraine, and any treatments for indications other than migraine that in the opinion of the clinician may interfere with the study objectives, e.g. antidepressants, anticonvulsants, beta-blockers, etc. for the duration of the study;
- •Women of childbearing potential must agree to use a medically effective form of contraception, unless they can confirm they've had bilateral tubal ligation or that their male partner has had a vasectomy (provided that the partner is the sole sexual partner of the trial participant and that the vasectomised partner has received medical assessment of the surgical success). Medically effective forms of contraception include hormonal methods, such as the contraceptive pill or implant (stable use for at least 3 months prior to enrolment), an intrauterine device (IUD) in use at least 30 days before enrolment, or barrier methods such as diaphragm plus spermicide or condom plus spermicide, in use at least 14 days before enrolment. In circumstances in which hormonal methods may interfere with the action of the IP or placebo, or in which the use of spermicides may increase the risk of transmission of disease, a double-barrier method is recommended.
- •Agree to refrain from making any drastic changes to their usual diet for the duration of the study, particularly periods of fasting;
- •Have a smartphone with Android or mobile operating system version compatible with eDiary;
- •Able to provide informed consent
排除标准
- •Under ketogenic diet, or using exogenous ketone supplements, e.g. medium chain triglycerides (MCT) 1 month prior to the initiation of the study or during the study;
- •Patients using regular high dose of Vitamin B3, calcium (>1 g/day) or magnesium (>350 mg/day) supplements 1 month prior to the initiation of the study or during the study;
- •Suffer from other primary (e.g. tension-type headache, trigeminal autonomic cephalalgias, other primary headache disorders) or secondary headaches (e.g. headaches attributed to trauma or injury, vascular or non-vascular intracranial disorders, substances or their withdrawal, infections, alterations of homeostasis), hemiplegic migraine;
- •Pregnancy or intending to become pregnant, or is of childbearing potential and has not had tubal ligation, has a male partner who has not had a successful vasectomy, and is unwilling to use a medically effective form of contraception, i.e. oral contraceptive pills, injectable, or implantable contraceptive; intrauterine device; or double-barrier method (e.g. diaphragm and condom), or is lactating during the study duration. In addition, women of child-bearing potential on hormone-based contraception should not intend to stop or change their contraceptive for the duration of the study;
- •Significant medical history, for example diabetes mellitus, renal stones, kidney and liver failure, somatic or psychiatric conditions, uncontrolled hypertension or medicated for hypertension, known hypercalcemia, history of or current cardiovascular disease, chronic gastrointestinal (GI) disease or intestinal malabsorption, or other illness, disease or syndrome which the investigators deem unsuitable to participate in the study;
- •Significant medication history, for example use of corticosteroids in format of oral or injectable;
- •Vaccination planned 2 weeks prior the start of the study, or during the study;
- •Patients following a sodium-restricted diet;
- •History of chronic alcohol or substance misuse;
- •Previously diagnosed food allergy;
- •Is participating in another clinical trial or has participated in a clinical trial the preceding month.
结局指标
主要结局
Mean change from baseline in MDM versus placebo
时间窗: 1 month
Headache eDiary will be used to record the change in monthly migraine frequency according to ICHD-3 guidelines. The headache diary captures information on date, time of onset and resolution, distinction of migraine from headache based on symptoms, pain intensity and use of acute medication
次要结局
- Proportion of responders: responders are defined as patients who had a greater than 50%, 75% or 100% reduction in MDM(1 month)
- Mean change from baseline in migraine intensity measured with a numerical rating scale from 1 to 10;(1 month)
- Incidence, severity and relatedness of adverse events(8 months)
- Mean change from baseline in the average migraine duration(1 month)
- Mean change from baseline in the number of headache days of any severity (headache, migraine or probable migraine, and migraine attacks)(1 month)
- Reduction in the use of acute medication for migraine(1 month)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
Unknown
The effect of acute oral ketone supplementation on the response of some appetite-related peptides to one-bout of sprint intermittent exercise in overweight meOverweight.Overweight and obesityIRCT20230721058875N1Shahid Beheshti University16
已完成
不适用
Exogenous Ketones in Type 2 DiabetesKetosisType 2 DiabetesNCT04194450University of British Columbia19
已完成
不适用
Therapeutic effect of ketogenic diet on survival and quality of patients with Glioblastoma MultiformeGlioblastoma multiforme.Malignant neoplasm of brainIRCT201204099417N1Vice chancellor for research, Tehran University of Medical Sciences20
Unknown
不适用
Ketone Supplementation in Individuals With PTSDPTSDKetosisNCT04083352Augusta University24
招募中
不适用
Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and RupturePatients With an Abdominal Aortic Aneurysm of 39-49 mm in DiameterNCT04723888RenJi Hospital300